Souhaitez-vous accéder aux communiqués récents ?

DENVER, June 13, 2025 (GLOBE NEWSWIRE) -- SHF Holdings, Inc., d/b/a Safe Harbor Financial (Nasdaq: SHFS) (“Safe Harbor” or the “Company”), a fintech leader facilitating financial services and credit...

Apex Labs Granted Israel MoH Approval to Expand Phase 2b Macrodose Psilocybin PTSD Clinical Trial.

Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Psychedelic Drugs Market 2025-2029" has been added to ResearchAndMarkets.com's offering. The psychedelic drugs market is poised for substantial...

PharmAla makes shipment to Yale, Agrees with Multidisciplinary Association for Psychedelic Studies to publicly post Investigator's Brochure for LaNeo MDMA

PharmAla warns the public that it does not sell MDMA to consumers, and to be on guard for illegitimate and fake products falsely being sold online.

PharmAla launches its Phenesafe AI, a custom-made technology stack allowing it to easily discover new MDMA-like molecules

PharmAla releases Q2 financial statements showing increased customer deposits, shipments

PsyCan Excoriates Trudeau Government for Making Assisted Suicide Harder than Psychedelic-Assisted Therapy; Calls on Carney and Poilievre to do better

PharmAla sidesteps tariff risk and expands clinical operations in the United States by contracting with Sharp Clinical Services as distribution partner

PharmAla completes shipment of MDMA to University of Washington, to be used in a Narcissism clinical trial. It also appoints Ali Taghva as CCO.